肺癌组织和肿瘤细胞系中BRG1的表达分析

BRG1（brahma—related gene 1）是进化上高度保守的SWI／SNF染色质重塑复合物的成员之一．研究表明：BRG1具有抑瘤基因的特征,可能与肿瘤的发生发展有关．我们采用RT—PCR、Northern杂交和Western blotting证实：肺腺癌细胞系A549和鼻咽癌细胞系HNE2、HNE3、CNE1中无BRG1的表达,而肺鳞癌细胞系NCI-H520、永生化正常人支气管上皮细胞系HBE和鼻咽癌细胞系HONE1、HNE1、CNE2中有BRG1的表达．同时,通过RT—PCR检测10例肺癌组织标本．发现60％（6／10）的肺癌组织中日RGG1的mRNA水平明显下调,而配对正常肺组织中BRG1的mRNA表达未见改变．对29例肺癌组织和10例配对正常肺组织切片进行免疫组化染色,结果显示：肺癌组织中BRG1蛋白表达的阳性率为37．9％（11／29）,配对正常肺组织中BRG1蛋白表达的阳性率为90％（9／10）,两者的差异有显著性（P〈0．05）．这提示BRG1确实在肺癌组织及多种肿瘤细胞系中表达下调或缺失,在肺癌发病过程中可能起一定的作用．     

PTPα高表达致NIH3T3细胞恶变早期相关基因的筛选与鉴定

利用已建立的蛋白质酪氨酸磷酸酶α(PTPα)诱导表达模型筛选NIH3T3细胞中PTPα诱导表达前后的差别表达基因 ,有利于探索肿瘤早期形成的机制。诱导PTPα表达 2 4h ,用差异显示逆转录PCR获得 6 5条差异片段 ,利用生物信息学方法分析这些差异片段 ,发现其中含有 2 9种已知基因、1 2种已知EST、6种未知EST ;对已知基因进行功能查询和分析 ,发现它们分别与信号转导、细胞骨架及粘附、转录与翻译、能量代谢、凋亡及核糖体蛋白质相关 ,其中G蛋白基因、TCR基因、类Trx基因、小窝蛋白 1 (caveolin 1 )基因经RT PCR及Northern印迹实验证实了差异表达的真实性。结果表明 ,PTPα诱导表达 2 4h后多种基因发生了表达变化 ,涉及细胞生理多方面的功能 ,其中一些基因在癌变的早期起重要的作用 ,这为深入探讨肿瘤早期形成机制打下基础 ,也可为基因治疗候选靶点的选择提供依据     

小鼠植入前胚胎紧密化相关基因Crg1的克隆

从已获得的运用抑制消减杂交技术(Suppression Subtractive Hybridization,SSH)分离、克隆和筛选代表8-细胞早期胚胎和紧密化8-细胞胚胎差别表达基因的ESTs片段(GenBank登录号：BQ740263、BQ740251)入手,经比较二者的同源性发现这两个EST末端反向互补,拼接成一个cDNA片段,经分析此序列包含一个完整的阅读框,提交给GenBank,登录号为AY134859。根据此序列设计引物从小鼠8-细胞紧密化胚胎cDNA中经PCR扩增出目的片段,克隆入pUCm—T载体后测序而获得全长cDNA,为小鼠植入前胚胎紧密化相关基因Crg1,分析比较证明Crg1基因与AY134859基本吻合。Crg1基因的cDNA全长为810bp,只有一个外显子,编码由150个氨基酸组成,分子量理论值为17．67kD的蛋白质。与最新的小鼠基因组工作草图进行电子杂交,该基因被定位在小鼠的14号染色体上。RT—PCR实验证明在小鼠植入前各个时期的胚胎、小鼠胚胎干细胞中均有表达,在小鼠胚胎成纤维细胞中没有表达。半定量RT—PCR实验证明Crg1基因在紧密化胚胎中表达较8—细胞胚胎高。采用Northern—blot手段分析Crg1基因在成年小鼠的8种组织中的表达情况,结果表明该基因只在小鼠卵巢中有微弱的表达,转录本大小为1．2kh,而在成年小鼠的脑、心脏、肾、睾丸、肝脏、肺、脾等中没有表达。研究表明,Crg1基因可能与小鼠胚胎紧密化及保持细胞的全能性相关。     

多核酶表达系统在HEK293细胞中对多药耐药相关蛋白（MRP1）的表达抑制作用

为了研究多核酶表达系统在HEK293细胞中对多药耐药相关蛋白表达抑制的作用．我们构建了含有20个可以自身切割的顺式作用核酶和10个靶向MRP1基因特定位点的反式作用核酶的多核酶表达系统。利用RT—PCR、Westem blot和MTT分析了多核酶系统分别与MRP1靶基因质粒和MRP1 全长基因质粒共转染的HEK293细胞。结果显示．多核酶表达系统能够明显降低荧光融合蛋白在HEK293细胞中的表达。RT—PCR分析表明．懈用靶mRNA降低程度与多核酶表达系统所含的反式作用核酶数目有关。Westernblot分析显示了与RT—PCR相似的结果。Mrrr分析表明,多核酶表达系统能够逆转由MRP1基因转染HEK293细胞产生的多药耐药性。结果提示．含有多个核酶的表达系统对MRP1基因的抑制效应优于单核酶的表达系统。因此．该策略可能用于基因治疗肿瘤或其他疾病．     

一个与化学因素致鼻咽癌相关的硝基还原酶基因的克隆与鉴定(英文)

在运用cDNAmicroarray分析鼻咽癌细胞系CNE1与正常鼻咽上皮细胞差异表达基因的基础上 ,发现ESTW 95 442在细胞系CNE1中存在明显表达下调 .随后采用生物信息学的方法克隆出了该EST所代表的硝基还原酶基因NOR1(GenBank登录号为AF4 6 2 348) .Northern印迹分析表明 ,该基因在脑、心脏、肺等正常组织中均有 2个转录产物 (1.6kb ,1.2kb) .RT PCR分析显示 ,NOR1基因在鼻咽癌活检组织中也存在表达下调 .但酶活性测定实验表明 ,它在鼻咽癌细胞系CNE1中的活性比正常鼻咽上皮细胞高 .通过基因转染实验发现NOR1基因具有与细菌硝基还原酶NTR相似的功能 ,能够将单功能烷基化试剂 2 硝基苯氮丙啶类化合物CB195 4的第 4位硝基还原成亚硝基从而生成细胞毒性物质 .研究结果表明 ,NOR1基因可能通过它的亚硝化作用及高活性而参与化学性因素致鼻咽癌的过程     

人肾高亲和力钠离子依赖性二羧酸转运蛋白基因的克隆和生物信息学分析

为探讨人高亲和力钠离子依赖性二羧酸转运蛋白 (humanhigh affinitysodium dependentdicar boxylatetransporter,hSDCT2orhNaDC3 )基因在人体内的生理功能及其与疾病的关系 ,借助生物信息学成功地从人肾中克隆了hSDCT2基因 (GenBank接收号 :AY0 72 810 ) .首先将大鼠SDCT2cDNA与人EST数据库进行同源性比较 ,获得具有高度同源性EST片段并用DNAstar软件将它们拼接成EST重叠群 .在重叠群上设计PCR引物从人肾总RNA中用RT PCR扩增出hSDCT2基因并测序 ,然后用软件对其结构特性、组织分布及基因定位进行分析 .序列测定结果显示 ,hSDCT2开放阅读框为180 9bp ,共编码 6 0 2个氨基酸 .蛋白同源性分析表明 ,其氨基酸序列与大鼠及小鼠SDCT2分别有85 %和 87%相同 .二级结构分析显示 ,该蛋白有 12个跨膜螺旋区 .Northern分析显示 ,该基因可在肾、肝、脑、胎盘等多种组织中表达 ,并定位于 2 0号染色体的q12～q13 1     

与泛肽途径可能相关的新基因UBAP1的克隆和表达分析

在先前确定了鼻咽癌9p21-22区域的一个最小共同缺失区内的基础上,为了筛选和克隆鼻咽癌相关的修选抑瘤基因,应用EST介导的定位候选克隆策略,用RT－PCR及Northern杂交检测了22个表达序列标签(expressed sequence tag,EST）在鼻咽癌细胞株HNE－1和原代培养的正常鼻咽上皮细胞中的表达水平,发现其中一个EST w56112在鼻咽癌细胞株HNE－1中的表达显著下调,RNA印迹显示其代表一转录本为2.7kb的基因。进一步运用cDNA测序和RACE方法克隆了该EST代表的基因全长cDNA,Genbank登录呈AF222043,同时结合生物信息学方法克了该基因在小鼠中的同源基因,Genbank登录AF275549。该基因cDNA全长2.7kb,编码由502个氨基酸组成的、分子质量为55kD的蛋白质。数据库分析显示该基因编码的蛋白质羧基段含有两个重要的泛肽相关结构域（UBA domain）,属于泛肽相关蛋白家族的一个新成员,因此征得国际人类基因组命名委员会同意,将其命名为UBAP1基因。运用Northern杂交和 RT-PCR方法检测发现UBAP1基因在所检测的人和小鼠的组织中广泛表达。采用RT－PCR和直接测序的方法,未能发现UBAP1基因编码区在鼻咽癌细胞株HNE－1和10例鼻咽癌活检标本中存在突变。UBAP1基因作为一个泛肽相关蛋白家族的新成员,有可能参与泛肽信号途径;结合其在9p的定位信息及在鼻咽癌中的表达下调。有等对UBAP1基因进行为精细的突变分析,以进一步研究其表达下调参与鼻咽癌发生发展的可能机制。     

牦牛CSRP3基因的克隆及组织表达分析

CSRP3基因(Cysteine and glycine-rich protein 3,CSRP3)编码CRP3蛋白,是一个肌发生的正调节因子,可通过多种方式在肌肉发育和肌肉细胞结构维持中起重要作用。通过对牦牛CSRP3基因进行克隆及组织表达谱分析,为后续提高牦牛肉品质的研究提供基础数据。采用RT-PCR方法克隆牦牛CSRP3基因CDS区;再对其进行序列分析及蛋白结构和功能预测等生物信息学分析;最后利用实时荧光定量PCR技术检测该基因在牦牛不同组织中的表达量。牦牛CSRP3基因CDS区长585 bp,编码194个氨基酸;CSRP3基因的系统进化树结果显示,牦牛与黄牛的亲缘性最近,其次是绵羊。牦牛CSRP3基因编码的蛋白为偏碱性不稳定亲水蛋白,无跨膜结构和信号肽,为非分泌蛋白,含有磷酸化位点22个,N-糖基化位点2个,O-糖基化位点7个;存在两个LIM结构域,属于LIM结构域蛋白质超家族成员,主要分布于细胞核中;二级结构以无规卷曲为主,三级结构的最佳模型为1b8t.1.A;实时荧光定量PCR结果显示,牦牛CSRP3基因在臀大肌中有较高表达量。生物信息学分析结果显示,CRP3蛋白含有两个LIM结构域,主要分布在细胞核中,实时荧光定量PCR结果显示牦牛CSRP3基因在臀大肌中具有较高表达量,为牦牛CSRP3基因在牦牛肉品质方面的调控机制研究提供了基础数据。     

小鼠一个新基因mLPTS的克隆、表达及亚细胞定位

利用EST拼接技术,RT－PCR及DNA序列测定,首次成功克隆了小鼠新基因mLPTS。获得的mLPTS基因片段长1244bp,编剧了一个由332个氨基酸组成的蛋白质。该蛋白质与人的LPTS蛋白有78％的同源性,LPTS基因是本实验室通过定位候选克隆策略获得的一个新的肝癌相关基因。它在肝癌组织中不表达或低表达,并参与细胞生长的负调控。小鼠mLPTS基因在小鼠的各个组织中都有表达,与人LPTS基因的表达组织分布相同。分析比较了LPTS蛋白在不同物种间的序列同源性,发现LPTS在进化上是高度保守的,是一个具有重要功能的基因。将mLPTS基因与绿色荧光蛋白EGFP融合构建真核表达载体,在中国仓鼠卵CHO细胞中表达,发现mLPTS基因表达产物位于细胞核仁中,为进一步研究该基因的功能及作用途径提供了重要信息。     

定位于染色体9p21-22的一个新基因UBAP1的克隆测序及在鼻咽癌中的表达分析

 在染色体 9p2 1 2 2鼻咽癌杂合性丢失 (lossofheterozygosity,LOH)高频区 ,应用EST介导的定位 侯选克隆策略 ,用RT PCR及Northern杂交检测了 2 2个表达序列标记 (expressedsequencetag ,EST)在鼻咽癌细胞株HNE1和原代培养的正常鼻咽上皮细胞中的表达差异 ,并对其中一个在鼻咽癌细胞株HNE1中表达下调的EST检测了在鼻咽癌活检组织中的表达 .用生物信息学方法获得其全长cDNA序列 ,GenBank登录号AF2 2 2 0 4 3.该基因cDNA全长 2 70 1bp ,其开放阅读框 (openreadingframe ,ORF)编码一个含 50 2个氨基酸、分子量为 55kD的碱性蛋白质 ,在蛋白羧基端含有 2个连续的重要UBA功能域 (ubiquitinassociateddomain) ,属于遍在蛋白相关蛋白家族的一个新成员 ,经国际人类基因命名委员会同意 ,将其命名为UBAP1 (ubiquitinassociatedprotein 1 ) .Northern表达分析显示UBAP1在所检测的人组织中广泛表达 ,但在人的心脏、骨骼肌及肝脏中的表达较强 .UBAP1基因在63 2 % ( 1 2 1 9)的鼻咽癌活检组织中表达下调 .UBAP1基因作为一个遍在蛋白相关蛋白家族的新成员 ,结合其在 9p的重要定位信息 ,有必要进一步研究其表达下调参与鼻咽癌发生发展的可能机制 .     

ENC1的克隆,原核表达与数种细胞系表达谱分析

以人 3月胎脑总RNA为模板 ,用RT PCR的方法得到了ENC1(ectoderm neuralcortex 1)基因的cDNA ,经测序证实该cDNA的长度为 180 0bp ,包含ENC1的完整编码区 .将之克隆入pGEX 4T 1载体构建重组表达质粒 ,转化大肠杆菌BL2 1表达 ,经Sepharose 4B纯化得到目的蛋白 .通过Northern印迹和RT PCR检验了该基因在数种细胞系中的表达 ,结果表明其在神经胶质母细胞瘤细胞系U2 5 1中有较高的表达 ,而在包括神经母细胞瘤细胞系SH SY5Y的其他数种细胞系中无表达 .与在正常生理状态下神经系统中两种细胞的表达情况相反 .这种分布不同的情况提示了ENC1在这两种不同来源的肿瘤的发生发展中具有不同作用     

Enlarged lateral ventricles and aberrant behavior in mice overexpressing PDGF-B in embryonic neural stem cells

Platelet-derived growth factor (PDGF) is important in central nervous system (CNS) development, and aberrant expression of PDGF and its receptors has been linked to developmental defects and brain tumorigenesis. We previously found that neural stem and progenitor cells in culture produce PDGF and respond to it by autocrine and/or paracrine signaling. We therefore aimed to examine CNS development after PDGF overexpression in neural stem cells in vivo.Transgenic mice were generated with PDGF-B under control of a minimal nestin enhancer element, which is specific for embryonic expression and will not drive adult expression in mice.The resulting mouse showed increased apoptosis in the developing striatum, which suggests a disturbed regulation of progenitor cells. Later in neurodevelopment, in early postnatal life, mice displayed enlarged lateral ventricles. This enlargement remained into adulthood and it was more pronounced in male mice than in transgenic female mice. Nevertheless, there was an overall normal composition of cell types and numbers in the brain and the transgenic mice were viable and fertile. Adult transgenic males, however, showed behavioral aberrations and locomotor dysfunction. Thus, a tightly regulated expression of PDGF during embryogenesis is required for normal brain development and function in mice.     

Polysialic acid facilitates tumor invasion by glioma cells

Polysialic acid (PSA) is thought to attenuate neural cell adhesion molecule (NCAM) adhesion, thereby facilitating neural cell migration and regeneration. Although the expression of PSA has been shown to correlate with the progression of certain tumors such as small cell lung carcinoma, there have been no studies to determine the roles of PSA in gliomas, the most common type of primary brain tumor in humans. In this study, we first revealed that among patients with glioma, PSA was detected more frequently in diffuse astrocytoma cells, which spread extensively. To determine directly the role of PSA in glioma cell invasion, we transfected C6 glioma cells with polysialyltransferases to express PSA. In those transfected cells, PSA is attached mainly to NCAM-140, whereas the mock-transfected C6 cells express equivalent amounts of PSA-free NCAM-140. Both PSA negative and positive C6 cell lines exhibited almost identical growth rates measured in vitro. However, PSA positive C6 cells exhibited increased invasion to the corpus callosum, where the mock-transfected C6 glioma cells rarely invaded when inoculated into the brain. By contrast, the invasion to the corpus callosum by both the mock-transfected and PSA positive C6 cells was observed in NCAM-deficient mice. These results combined indicate that PSA facilitates tumor invasion of glioma in the brain, and that NCAM-NCAM interaction is likely attenuated in the PSA-mediated tumor invasion.     

Extracellular ATP reduces tumor sphere growth and cancer stem cell population in glioblastoma cells

Glioblastoma is the most aggressive tumor in the CNS and is characterized by having a cancer stem cell (CSC) subpopulation essential for tumor survival. The purinergic system plays an important role in glioma growth, since adenosine triphosphate (ATP) can induce proliferation of glioma cells, and alteration in extracellular ATP degradation by the use of exogenous nucleotidases dramatically alters the size of gliomas in rats. The aim of this work was to characterize the effect of the purinergic system on glioma CSCs. Human U87 glioma cultures presented tumor spheres that express the markers of glioma cancer stem cells CD133, Oct-4, and Nanog. Messenger RNA of several purinergic receptors were differently expressed in spheres when compared to a cell monolayer not containing spheres. Treatment of human gliomas U87 or U343 as well as rat C6 gliomas with 100 μM of ATP reduced the number of tumor spheres when grown in neural stem cell medium supplemented with epidermal growth factor and basic fibroblast growth factor. Moreover, ATP caused a decline in the number of spheres observed in culture in a dose-dependent manner. ATP also reduces the expression of Nanog, as determined by flow cytometry, as well as CD133 and Oct-4, as analyzed by flow cytometry and RT-PCR in U87 cells. The differential expression of purinergic receptor in tumor spheres when compared to adherent cells and the effect of ATP in reducing tumor spheres suggest that the purinergic system affects CSC biology and that ATP may be a potential agonist for differentiation therapy.     

Brain heterogeneity leads to differential innate immune responses and modulates pathogenesis of viral infections

The central nervous system (CNS) is a highly complex organ with highly specialized cell subtypes. Viral infections often target specific structures of the brain and replicate in certain regions. Studies in mice deficient in type I Interferon (IFN) receptor or IFN-β have highlighted the importance of the type I IFN system against viral infections and non-viral autoimmune disorders in the CNS. Direct antiviral effects of type I IFNs appear to be crucial in limiting early spread of a number of viruses in CNS tissues. Increased efforts have been made to characterize IFN expression and responses in the brain. In this context, it is important to identify cells that produce IFN, decipher pathways leading to type I IFN expression and to characterize responding cells. In this review we give an overview about region specific aspects that influence local innate immune responses. The route of entry is critical, but also the susceptibility of different cell types, heterogeneity in subpopulations and micro-environmental cues play an important role in antiviral responses.Recent work has outlined the tremendous importance of type I IFNs, particularly in the limitation of viral spread within the CNS. This review will address recent advances in understanding the mechanisms of local type I IFN production and response, in the particular context of the CNS.     

The role of the insulin-like growth factors in the central nervous system

Increasing evidence strongly supports a role for insulin-like growth factor-I (IGF-I) in central nervous system (CNS) development. IGF-I, IGF-II, the type IIGF receptor (the cell surface tyrosine kinase receptor that mediates IGF signals), and some IGF binding proteins (IGFBPs; secreted proteins that modulate IGF actions) are expressed in many regions of the CNS beginningin utero. The expression pattern of IGF system proteins during brain growth suggests highly regulated and developmentally timed IGF actions on specific neural cell populations. IGF-I expression is predominantly in neurons and, in many brain regions, peaks in a fashion temporally coincident with periods in development when neuron progenitor proliferation and/or neuritic outgrowth occurs. In contrast, IGF-II expression is confined mainly to cells of mesenchymal and neural crest origin. While expression of type I IGF receptors appears ubiquitous, that of IGFBPs is characterized by regional and developmental specificity, and often occurs coordinately with peaks of IGF expression. In vitro IGF-I has been shown to stimulate the proliferation of neuron progenitors and/or the survival of neurons and oligodendrocytes, and in some cultured neurons, to stimulate function. Transgenic (Tg) mice that overexpress IGF-I in the brain exhibit postnatal brain overgrowth without anatomic abnormality (20–85% increases in weight, depending on the magnitude of expression). In contrast, Tg mice that exhibit ectopic brain expression of IGFBP-1, an inhibitor of IGF action when present in molar excess, manifest postnatal brain growth retardation, and mice with ablated IGF-I gene expression, accomplished by homologous recombination, have brains that are 60% of normal size as adults. Taken together, these in vivo studies indicate that IGF-I can influence the development of most, if not all, brain regions, and suggest that the cerebral cortex and cerebellum are especially sensitive to IGF-I actions. IGF-I’s growth-promoting in vivo actions result from its capacity to increase neuron number, at least in certain populations, and from its potent stimulation of myelination. These IGF-I actions, taken together with its neuroprotective effects following CNS and peripheral nerve injury, suggest that it may be of therapeutic benefit in a wide variety of disorders affecting the nervous system.     

Expression of erythropoietin receptor mRNA in mouse brain hemispheres

Now there is a growing evidence that erythropoietin receptors (Epo-R) are present also in some nonhematopoietic tissues such as endothelial cells and fetal cells of neural origin, although the physiological role of Epo-R at these sites is unclear. There are some speculations that Epo-R may be expressed on cells only in the developing CNS. The objective of this study was to determine whether Epo-R mRNA may be expressed in the brain hemispheres of Balb/c mice of different age groups: 1) newborn mice, 2) young 2 months old mice, 3) old 1.8 year old mice. We also studied the in vivo effect of recombinant erythropoietin on the expression of Epo-R mRNA in the brain hemispheres of (CBA x C57BL)F1 mice by RT-PCR. We have detected the existence of Epo-R mRNA expression in brain hemispheres of all the groups, but in old mice this expression was significantly higher. We have discovered a decrease in Epo-R mRNA expression in brain hemispheres of (CBA x C57BL)F1 mice 24 h after in vivo administration of recombinant erythropoietin. The Epo-R mRNA expression in the left brain hemispheres of (CBA x C57BL)F1 was considerably higher than in the right one.     

The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility

The adult neural parenchyma contains a distinctive extracellular matrix that acts as a barrier to cell and neurite motility. Nonneural tumors that metastasize to the central nervous system almost never infiltrate it and instead displace the neural tissue as they grow. In contrast, invasive gliomas disrupt the extracellular matrix and disperse within the neural tissue. A major inhibitory component of the neural matrix is the lectican family of chondroitin sulfate proteoglycans, of which brevican is the most abundant member in the adult brain. Interestingly, brevican is also highly up-regulated in gliomas and promotes glioma dispersion by unknown mechanisms. Here we show that brevican secreted by glioma cells enhances cell adhesion and motility only after proteolytic cleavage. At the molecular level, brevican promotes epidermal growth factor receptor activation, increases the expression of cell adhesion molecules, and promotes the secretion of fibronectin and accumulation of fibronectin microfibrils on the cell surface. Moreover, the N-terminal cleavage product of brevican, but not the full-length protein, associates with fibronectin in cultured cells and in surgical samples of glioma. Taken together, our results provide the first evidence of the cellular and molecular mechanisms that may underlie the motility-promoting role of brevican in primary brain tumors. In addition, these results underscore the important functional implications of brevican processing in glioma progression.     

EphA2对神经胶质瘤细胞系U251的凋亡﹑增殖﹑迁移和侵袭的研究

为了研究EphA2对神经胶质瘤细胞系U251在增殖、凋亡、迁移和侵袭方面所起的作用,用RT-PCR方法检测正常脑组织标本与两种恶性胶质瘤细胞系中EphA2 mRNA表达水平,然后用化学合成的针对EphA2基因的小干扰RNA(siRNA)下调该基因的表达,以检测其在U251中的生物学功能．证实了EphA2基因在正常脑组织标本中的表达水平远低于两种恶性胶质瘤细胞系．把体外化学合成针对EphA2基因的小干扰RNA(siRNA- EphA2)转染入U251细胞后,Western blot, 实时定量 RT-PCR检测到U251细胞中EphA2蛋白及mRNA表达水平都明显降低,并且细胞增殖受到显著抑制,同时出现了明显的细胞凋亡．伤口愈合实验(检测细胞迁移能力),Transwell小室实验(检测细胞侵袭能力)均表明,下调EphA2的表达后,细胞的迁移和侵袭能力较阴性对照组显著减弱．上述结果表明,在神经胶质瘤U251细胞中,EphA2与其恶性增殖及高度侵染性相关,可作为分子治疗的有效靶点．